For Transcarent CEO Glen Tullman, there is a strong case to buy telehealth behemoth Teladoc – the very company that acquired Tullman’s last company, Livongo for $18.5 billion. Tullman could buy back the entirety of Teladoc for less than a quarter of what it bought Livongo for just two years ago
Flight Of The Healthcare Navigators: Why Glen Tullman’s Best Magic Trick Yet May Be Buying Teladoc
